Person: KOCA, DAVUT
Loading...
Email Address
Birth Date
3 results
Search Results
Now showing 1 - 3 of 3
Publication Positive effect of autologous platelet rich plasma on saanen buck semen cryopreservation in non-breeding season(Academic Press Inc Elsevier Science, 2021-12-01) Alçay, Selim; Aktar, Ahmet; Koca, Davut; Kılıç, Mehmet Ali; Akkaşoğlu, Mustafa; Sağırkaya, Hakan; ALÇAY, SELİM; Aktar, Ahmet; KOCA, DAVUT; Kılıç, M. Ali; Akkaşoğlu, Mustafa; SAĞIRKAYA, HAKAN; Bursa Uludağ Üniversitesi/Veteriner Fakültesi/Üreme ve Suni Tohumlama Anabilim Dalı; Bursa Uludağ Üniversitesi/Veteriner Fakültesi/Doğum ve Jinekoloji Bölümü; 0000-0002-2975-2594; 0000-0002-7962-6959; 0000-0003-4482-3490; AAI-6709-2021; C-7150-2016; CBC-7350-2022; CBC-1744-2022; EMD-6376-2022; DPO-0081-2022The objective of the current study was to evaluate the effect of autologous platelet-rich plasma (PRP) addition into soybean lecithin based extender on buck semen at post-thaw. Semen samples were collected from eight Saanen buck, and each semen sample was split into four equal aliquots and diluted with different concentrations of PRP supplemented extenders [no PRP (control), 0.5 x 107/ml PRP, 1 x 107/ml PRP, or 2 x 107/ml PRP]. Motility, plasma membrane functional integrity, acrosome integrity, mitochondrial membrane potential, DNA integrity and malondialdehyde concentrations (MDA) were measured and analyzed at post-thaw. The results showed that 2 x 107/ml PRP group had a positive effect on motility (62.41 +/- 4.24), membrane functional integrity (71.11 +/- 2.90), mitochondrial membrane potential (69.70 +/- 1.99), DNA integrity (7.22 +/- 0.93) and MDA levels (2.56 +/- 0.73) at post-thaw (P < 0.05). The results of the study demonstrated that autologous PRP has a protective effect on cryopreservation of buck spermatozoa and the fertility effects are worthy of further study.Publication Efficacy and toxicity of doxorubicin and cyclophosphamide for the neoadjuvant treatment of locally advanced stage canine mammary tumors(Kafkas Univ, Veteriner Fakultesi Dergisi, 2020-11-01) Shahzad, Abid Hussain; Kuruoglu, Fikriye Ecem; Özyiğit, Musa Özgür; ÖZYİĞİT, MUSA ÖZGÜR; Nak, Deniz; NAK, DENİZ; Küpeli, Zehra Avcı; Ekici, Zeynep Merve; Koca, Davut; KOCA, DAVUT; Avcılar, Talha; Nak, Yavuz; NAK, YAVUZ; Sahin, Mustafa Eren; ; Bursa Uludağ Üniversitesi/Veteriner Fakültesi/Doğum ve Jinekoloji Anabilim Dalı.; 0000-0002-6715-8529; 0000-0003-1853-4679; 0000-0002-7962-6959; 0000-0001-7034-9644; 0000-0002-8623-8292; AAH-5494-2021; AAH-2873-2021; AAI-6709-2021; AAR-6478-2021The aim of this study was to investigate the effect and toxicity of a doxorubicin cyclophosphamide combination for neoadjuvant use in dogs with locally advanced mammary tumors. A total of 16 dogs with locally advanced mammary tumors aged 8-14 years was used in this study. Samples were taken from all the dogs via Tru-Cut biopsy and fine needle aspiration biopsy of the lymph nodes prior to neoadjuvant chemotherapy. The samples were sent to the pathology laboratory for histopathological examination. Based on the histopathology results, mammary tumors were diagnosed as adenocarcinoma (n=13), tubulopapillary carcinoma (n=2) and malignant mixed tumors (n=1). For the neoadjuvant chemotherapy, doxorubicin (25-30 mg/m(2)) and cyclophosphamide (100 mg/m(2)) were administered via slow IV injection 4 times at 3-week intervals. Clinical findings such as fever, vomiting, anorexia, lethargy, weight loss, alopecia, enteritis, hematuria, and skin ulceration and laboratory findings such as a decrease in neutropenia and hematocrit values were observed. Based on the longest diameter of the tumors before and after four weeks of chemotherapy, a complete response was detected in 2 dogs (12.5%), a partial response was observed in 9 dogs (56.25%) and the disease was stable in 5 dogs (31.25%). According to results, the toxicity, and efficacy of a doxorubicin and cyclophosphamide combination for neoadjuvant chemotherapy in dogs with locally advanced mammary tumors is acceptable, and the treatment is promising.Publication Administration of meloxicam to cows experiencing dystocia does not increase the incidence of retained placenta(Georg Thieme Verlag Kg, 2019-10-01) Kunz, Fabian; Failing, Klaus; Wehrend, Axel; Sendag, Sait; KOCA, DAVUT; Bursa Uludağ Üniversitesi/Veteriner Fakültesi/Jinekoloji ve Doğum Anabilim Dalı.; 0000-0002-7962-6959; AAI-6709-2021Objective The post partum use of analgesics in cows has increased in consequence to society's increased awareness of animal welfare. However, it is known that the post partum administration of a subset of nonsteroidal anti-inflammatory drugs to cows may lead to an increased rate of retained placenta. Therefore, the aim of this study was clarify, whether a single administration of meloxicam to cows that experienced dystocia results in an increased rate of this disease.Material and methods The study was conducted in 63 Holstein-Friesian cows in 4 farms with random allocation into 2 groups: In animals of the treatment group (n = 27) a single subcutaneous injection of meloxicam (0.5 mg/kg) was administered within 2-8 hours after calving. The animals of the control group (n = 36) received the same volume of a bovine infusion solution (Amynin (R), bovine infusion solution, Boehringer Ingelheim) subcutaneously. A clinical examination of the cows was performed on the day of parturition and on the 21st day post partum. Findings on the days in between were obtained by questioning of the farmers. The exact Fisher-test was calculated in order to test for statistical differences between the treatment and control groups.Results In cows of the treatment group, retained placenta was not observed more frequently than in cows of the control group.Conclusion and clinical relevance A single administration of meloxicam to cows that experienced dystocia does not increase the incidence of retained placenta.